JSA Advocates and Solicitors (JSA) advised IvyCap on its investment in CureBay Technologies Private Limited (“CureBay”) as part of CureBay’s Pre-Series C round, alongside Bertelsmann Nederland B.V., EE-FI AIF (Elevar), British International Investment PLC and VentureSoul Capital Fund I – Scheme 1 (the existing investors of the Company). The investment was a mix of primary subscription and secondary purchase of shares from existing shareholders.
CureBay operates a technology-led rural healthcare group, delivering primary and secondary care through a hub-and-spoke network of e-clinics across Odisha, Bihar, Jharkhand, Chhattisgarh, Madhya Pradesh and Uttar Pradesh, supported by teleconsultation, diagnostics, hospital concierge services, retail pharmacy and subscription healthcare plans.
JSA’s mandate covered the legal due diligence on the Indian group companies and the US subsidiary, and drafting, review and negotiation of the transaction documents.
The JSA team was led by Minhaz Lokhandwala, Partner and comprised Rohit Jain, Principal Associate; Riya Gupta, Principal Associate; Sanjana Sreenath, Associate; Aditya Jain, Associate; Vaastu Tyagi, Associate; Vidushi Sehgal, Associate and Soumyajit Haldar, Associate.
Minhaz is a private equity, venture capital and M&A lawyer with an experience of 16 years. He regularly advises clients on domestic and cross border transactions representing acquirers / investors, both financial and strategic and promoters. He has successfully led large and complex transactions for Indian and global corporations.